Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Cash from Operations: 2010-2025

Historic Cash from Operations for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $3.2 million.

  • OptimizeRx's Cash from Operations rose 7878.28% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year increase of 12750.77%. This contributed to the annual value of $4.9 million for FY2024, which is 16752.76% up from last year.
  • Latest data reveals that OptimizeRx reported Cash from Operations of $3.2 million as of Q3 2025, which was up 7878.28% from $4.6 million recorded in Q2 2025.
  • Over the past 5 years, OptimizeRx's Cash from Operations peaked at $4.6 million during Q2 2025, and registered a low of -$6.3 million during Q4 2023.
  • Moreover, its 5-year median value for Cash from Operations was $1.5 million (2023), whereas its average is $1.1 million.
  • In the last 5 years, OptimizeRx's Cash from Operations crashed by 86883.63% in 2023 and then surged by 256279.07% in 2024.
  • OptimizeRx's Cash from Operations (Quarter) stood at -$1.3 million in 2021, then skyrocketed by 310.07% to $2.8 million in 2022, then crashed by 323.22% to -$6.3 million in 2023, then soared by 103.16% to $198000.0 in 2024, then soared by 1517.17% to $3.2 million in 2025.
  • Its Cash from Operations was $3.2 million in Q3 2025, compared to $4.6 million in Q2 2025 and $3.9 million in Q1 2025.